Table 1.
ICBs that are approved in clinic
| Drugs | Pharmacy | Target | Indication |
|---|---|---|---|
| Opdivo (Nivolumab) | BMS | Programmed cell death-1(PD-1) | Melanoma, Non-small cell lung cancer, Renal cell carcinoma, Classical hodgkin lymphoma, Squamous Cell Carcinoma of Head and Neck, Bladder cancer, Gastric cancer, Hepatocellular carcinoma, Microsatellite high/Mismatch repair deficiency colorectal cancer |
| Keytruda (Pembrolizumab) | MSD | Programmed cell death-1(PD-1) | Melanoma, Non-small cell lung cancer, Head and neck squamous carcinoma, Classical hodgkin lymphoma, Squamous Cell Carcinoma of Head and Neck, Bladder cancer, Hepatocellular carcinoma, Gastric cancer, Microsatellite high/Mismatch repair deficiency solid tumor |
| Tecentric (Atezolizumab) |
Roche | Programmed cell death-1(PD-1) | Bladder cancer、Non-small cell lung cancer |
| Bavencio (avelumab) | Merck | Programmed cell death ligand-1(PD-L1) | Bladder cancer、Merkel cell carcinoma |
| Imfinzi (durvalumab) |
Astrazeneca | Programmed cell death ligand-1(PD-L1) | Bladder cancer |
| Yervoy (Ipilimumab) | BMS | CTLA-4 | Melanoma |